These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23752064)

  • 1. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.
    Pitta CA; Papageorgis P; Charalambous C; Constantinou AI
    Cancer Lett; 2013 Sep; 337(2):167-76. PubMed ID: 23752064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells.
    Zhang L; Ren X; Cheng Y; Huber-Keener K; Liu X; Zhang Y; Yuan YS; Yang JW; Liu CG; Yang JM
    Biochem Pharmacol; 2013 Sep; 86(6):726-33. PubMed ID: 23856293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
    Jang ER; Lim SJ; Lee ES; Jeong G; Kim TY; Bang YJ; Lee JS
    Oncogene; 2004 Mar; 23(9):1724-36. PubMed ID: 14676837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
    Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
    Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
    Yang X; Phillips DL; Ferguson AT; Nelson WG; Herman JG; Davidson NE
    Cancer Res; 2001 Oct; 61(19):7025-9. PubMed ID: 11585728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.
    Zhang B; Zhang X; Tang B; Zheng P; Zhang Y
    Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
    Fan J; Yin WJ; Lu JS; Wang L; Wu J; Wu FY; Di GH; Shen ZZ; Shao ZM
    J Cancer Res Clin Oncol; 2008 Aug; 134(8):883-90. PubMed ID: 18264725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
    Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
    Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
    Sharma D; Saxena NK; Davidson NE; Vertino PM
    Cancer Res; 2006 Jun; 66(12):6370-8. PubMed ID: 16778215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing is everything: order of administration of 5-aza 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity.
    Hostetter CL; Licata LA; Keen JC
    Cancer Lett; 2009 Mar; 275(2):178-84. PubMed ID: 19013015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
    Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
    Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling.
    Badia E; Duchesne MJ; Semlali A; Fuentes M; Giamarchi C; Richard-Foy H; Nicolas JC; Pons M
    Cancer Res; 2000 Aug; 60(15):4130-8. PubMed ID: 10945620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
    Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
    J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
    Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
    Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of exogenous ER beta expression on the cell growth properties of MCF-7 breast cancer cell line].
    Zhu JH; Ye QN; Song ST; Jiang ZF; Yan JH; Hao CF; Huang CF
    Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):103-6. PubMed ID: 16750012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
    Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
    Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.
    Hodges-Gallagher L; Valentine CD; Bader SE; Kushner PJ
    Breast Cancer Res Treat; 2007 Nov; 105(3):297-309. PubMed ID: 17186358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.